Printer Friendly

THERAGENICS ANNOUNCES EXECUTIVE APPOINTMENTS

 ATLANTA, May 12 /PRNewswire/ -- Theragenics Corp. (NASDAQ: THRX), an Atlanta-based cancer therapy company, announced today that, at the May 8, 1993, meeting of the board of directors, John V. Herndon was reelected to serve as chairman of the corporation, Christine Jacobs was renamed president and elected chief executive officer, and Bruce Smith was again named secretary, treasurer and chief financial officer.
 In a separate action, two new members were added to Theragenics' medical advisory committee, which provides advice and counsel to the board of directors and Theragenics management at the request of the board. The new members are John C. Blasko, M.D., clinical professor of radiation oncology at the University of Washington, director of the Northwest Tumor Institute in Seattle, Wash., and member of the board of directors of the King County Washington Unit of the American Cancer Society; and Ravinder Nath, Ph.D., F.A.C.R., professor of therapeutic radiology (radiological physics) at Yale University, member of the Radiation Study Section of the National Institutes of Health and president-elect of the American Association of Physicists in Medicine.
 Theragenics manufactures and markets TheraSeed, a nonsurgical, outpatient treatment which uses implanted Palladium 103 seeds to eradicate prostate cancer.
 -0- 5/12/93
 /CONTACT: Bruce Smith, chief financial officer of Theragenics Corp., 404-381-8338, or Rick Eisenberg of Eisenberg Communications, 212-496-6828, for Theragenics Corp./
 (THRX)


CO: Theragenics Corp. ST: Georgia IN: HEA SU: PER

PS-OS -- NY026 -- 7452 05/12/93 09:59 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 12, 1993
Words:242
Previous Article:THERAGENICS REPORTS REVENUES AND EARNINGS FOR FIRST QUARTER OF 1993
Next Article:PERSONAL DIAGNOSTICS, INC. REPORTS NET INCOME OF $265,000 ($.05 PER SHARE) IN SECOND FISCAL QUARTER
Topics:


Related Articles
THERAGENICS ANNOUNCES THIRD QUARTER RESULTS; QUARTERLY PROFITS INCREASE NEARLY THREE-FOLD; REVENUES ALSO SOAR
THERAGENICS ADDS CHARLES KLIMKOWSKI TO BOARD OF DIRECTORS; COMPANY ALSO RETAINS ALEX. BROWN & SONS AS FINANCIAL ADVISOR
THERAGENICS REPORTS REVENUES AND EARNINGS FOR FIRST QUARTER OF 1993
THERAGENICS ANNOUNCES SECOND QUARTER RESULTS
THERAGENICS ANNOUNCES THIRD QUARTER RESULTS
THERAGENICS SETS ANNUAL MEETING DATE
THERAGENICS REPORTS REVENUES AND EARNINGS FOR FIRST QUARTER OF 1994
STUDY: 91 PERCENT OF PROSTATE CANCER PATIENTS DISEASE FREE FIVE YEARS AFTER IMPLANT THERAPY; THERAGENICS' THERASEED IMPLANT USED IN STUDY
THERAGENICS REPORTS SECOND QUARTER 1994 EARNINGS
Theragenics Corporation(R) Announces Re-election of Directors After Annual Meeting.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters